$32,000
Est. net congressional buying / selling (2 years). Updated Jan 14, 2026

Are Members of Congress Buying or Selling Astrazeneca?

No members of Congress have reported trading Astrazeneca (AZN) stock in the past 90 days. The history below covers the past two years.

Congressional trading is one of the alternative data signals AltIndex tracks as part of the AZN AI Score. For corporate insider activity, see AZN insider transactions. To browse trades across every ticker, visit the Congress Trading tracker.

Which Congress Members Are Trading Astrazeneca?

Member of CongressActivityTradesLast Trade
Lisa McClain Mixed $32,000 4 Oct 31, 2025
Gilbert Cisneros Bought $24,000 3 Dec 18, 2025
Bruce Westerman Mixed $16,000 2 Apr 21, 2025
Valerie Hoyle Bought $8,000 1 Oct 29, 2024
Val Hoyle Sold $8,000 1 Sep 23, 2025
Julia Letlow Bought $8,000 1 Dec 8, 2025

AZN Congressional Trade History

Member of CongressTrade DateTypeEstimated Size
Gilbert Cisneros Dec 18, 2025 Buy $1K – $15K
Julia Letlow Dec 8, 2025 Buy $1K – $15K
Gilbert Cisneros Nov 19, 2025 Buy $1K – $15K
Lisa McClain Oct 31, 2025 Sell $1K – $15K
Lisa McClain Oct 30, 2025 Sell $1K – $15K
Gilbert Cisneros Oct 21, 2025 Buy $1K – $15K
Val Hoyle Sep 23, 2025 Sell $1K – $15K
Lisa McClain Jul 22, 2025 Buy $1K – $15K
Lisa McClain Jun 9, 2025 Buy $1K – $15K
Bruce Westerman Apr 21, 2025 Sell $1K – $15K
Bruce Westerman Mar 3, 2025 Buy $1K – $15K
Valerie Hoyle Oct 29, 2024 Buy $1K – $15K

Frequently Asked Questions: Astrazeneca Congress Trading

No members of Congress have reported buying or selling AZN stock in the past 90 days. Congressional trades are disclosed under the STOCK Act — view the full history on this page.

Some research has found that congressional stock trades have at times outperformed the market, possibly due to informational advantages. AltIndex tracks these trades as one of 25+ signals in the AI Score. See the full Congress Trading tracker for all recent trades.

Gilbert Cisneros bought Astrazeneca (AZN) stock most recently, on December 18, 2025.

The estimated net value of congressional trades in Astrazeneca over the past 2 years is positive, at $32,000, meaning members of Congress have on balance bought more than they have sold.

Members of Congress can have early visibility into legislation, regulation, and government contracts that may affect a company. Tracking their disclosed trades — alongside other signals — can offer additional context for investment decisions.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.